Adult Burkitt lymphoma: Advances in diagnosis and treatment

Ibrahim T. Aldoss, Dennis D. Weisenburger, Kai Fu, Wing C. Chan, Julie M. Vose, Philip J. Bierman, R. Gregory Bociek, James O. Armitage

Research output: Contribution to journalArticlepeer-review

42 Scopus citations

Abstract

Burkitt lymphoma is a unique B-cell malignancy with a high proliferation rate and characteristic genetic changes involving the c-myc oncogene. Burkitt lymphoma is common in children but also occurs in adults, where distinction from diffuse large B-cell lymphoma may pose a problem. The development of brief, very intensive chemotherapy regimens has led to a very high cure rate in children with Burkitt lymphoma. The use of these regimens in adults, often in combination with the antibody rituximab (Rituxan), has also made the cure of a majority of adults possible. Burkitt lymphoma in adults cannot be treated effectively with the common regimens used for diffuse large B-cell lymphoma such as CHOP-R (cyclophosphamide, doxorubicin HCl, vincristine [Oncovin], prednisone, rituximab). Prompt diagnosis and initiation of appropriate therapy with attention to the possibility of tumor lysis syndrome are necessary for optimal results.

Original languageEnglish (US)
Pages (from-to)1508-1517
Number of pages10
JournalONCOLOGY
Volume22
Issue number13
StatePublished - Nov 30 2008

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Adult Burkitt lymphoma: Advances in diagnosis and treatment'. Together they form a unique fingerprint.

Cite this